Topic: S1 Protein

Research into the S1 spike protein suggests it may be the primary driver of COVID-19 pathology. Some theories, previously discussed in early 2020, suggest that nicotine may interact with ACE2 receptors to prevent viral entry. While these claims were largely suppressed, tobacco giant Altria has recently expanded into medical inhalers and nicotine gum, signaling a potential shift toward therapeutic applications.